Modulation of gene expression in human central nervous system tumors under methionine deprivation-induced stress

Cancer Research

Volumn 64, Issue 20, 2004, Pages 7513-7525

  Kokkinakis, Demetrius M ^a   Liu, Xiaoyan ^a   Chada, Sunil ^c   Ahmed, Mansoor M ^b   Shareef, Mohammed M ^b   Singha, Ujjal K ^a   Yang, Sutin ^a   Luo, Jianhua ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c Introgen Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; METHIONINE; PROTEIN MAD1; PROTEIN P21; SMAD2 PROTEIN; SMAD5 PROTEIN; SMAD7 PROTEIN; SOMATOMEDIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

APOPTOSIS; ARTICLE; ASTROCYTOMA; CELL CYCLE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CYTOTOXICITY; GENE EXPRESSION; GENE TRANSLOCATION; GENETIC LINKAGE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MEDULLOBLASTOMA; NERVOUS SYSTEM TUMOR; PRIORITY JOURNAL; PROTEIN SYNTHESIS; STRESS; TUMOR CELL; UPREGULATION; XENOGRAFT;

APOPTOSIS; ASTROCYTOMA; CELL CYCLE; CELL LINE, TUMOR; CENTRAL NERVOUS SYSTEM NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEDULLOBLASTOMA; METHIONINE; NF-KAPPA B;

EID: 5644280149     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0592     Document Type: Article

References (66)

1. Halpern BC, Clark BR, Hardy DN, Halpern RM, Smith RA. The effect of replacement of MET by homocystine on survival of malignant and normal adult mammalian cells in culture. Proc Natl Acad Sci USA 1974;71:1133-6.
2. Judde JG, Ellis M, Frost P. Biochemical analysis of the role of transmethylation in the MET dependence of tumor cells. Cancer Res 1989;49:4859-65.
3. Kokkinakis DM, Hoffman RM, Frenkel EP, et al. Synergy between MET stress and chemotherapy in the treatment of brain tumor xenografts in athymic mice. Cancer Res 2001;61:4017-23.
4. Kokkinakis DM, Wick JB, Zhou QX. Metabolic response of normal and malignant tissue to acute and chronic MET stress in athymic mice bearing human glial tumor xenografts. Chem Res Toxicol 2002;15:1472-9.
5. Kokkinakis DM, Schold SC Jr, Hori H, Nobori T. Effect of long-term depletion of plasma MET on the growth and survival of human brain tumor xenografts in athymic mice. Nutr Cancer 1997;29:195-204.
6. Kokkinakis DM, von Wronski MA, Vuong TH, Brent TP, Schold SC Jr. Regulation of O6- methylguanine-DNA methyltransferase by MET in human tumour cells. Br J Cancer 1997;75:779-88.
7. Bocangel DB, Finkelstein S, Schold SC, et al. Multifaceted resistance of gliomas to temozolomide. Clin Cancer Res 2002;8:2725-34.
8. Lupberger J, Kreuzer KA, Baskaynak G, et al. Quantitative analysis of beta-actin, beta-2-microglobulin and porphobilinogen deaminase mRNA and their comparison as control transcripts for RT-PCR. Mol Cell Probes 2002;16:25-30.
9. Rao PN, Johnson RT. Mammalian cell fusion: studies on the regulation of DNA synthesis and mitosis. Nature (Lond) 1970;225:159-64.
10. Nurse P. A long twentieth century of the cell cycle and beyond. Cell 2000;100:71-8.
11. Verona R, Moberg K, Estes S, et al. E2F activity is regulated by cell cycle-dependent changes in subcellular localization. Mol Cell Biol 1997;17:7268-82.
12. Mukaida N, Mahe Y, Matsushima K. Cooperative interaction of nuclear factor-kappa B- and cis-regulatory enhancer binding protein-like factor binding elements in activating the interleukin-8 gene by pro-inflammatory cytokines. J Biol Chem 1990;265:21128-33.
13. Yasumoto K, Okamoto S, Mukaida N, et al. Tumor necrosis factor alpha and interferon gamma synergistically induce interleukin 8 production in a human gastric cancer cell line through acting concurrently on AP-1 and NF-kB-like binding sites of the interleukin 8 gene. J Biol Chem 1992;267:22506-11.
14. Brasier AR, Jamaluddin M, Casola A, et al. A promoter recruitment mechanism for tumor necrosis factor-alpha-induced interleukin-8 transcription in type II pulmonary epithelial cells. Dependence on nuclear abundance of Rel A, NF-kappaB1, and c-Rel transcription factors. J Biol Chem 1998;273:3551-61.
15. Ishimitsu T, Tsukada K, Minami J, Ono H, Matsuoka H. Variations of human adrenomedullin gene and its relation to cardiovascular diseases. Hypertens Res 2003;26(Suppl):SI29-34.
16. Harant H, Eldershaw SA, Lindley IJ. Human macrophage inflammatory protein-3alpha/CCL20/LARC/Exodus/SCYA20 is transcriptionally upregulated by tumor necrosis factor-alpha via a nonstandard NF-kappaB site. FEBS Lett 2001;509:439-45.
17. Chada S, Sutton RB, Ekmekcioglu S, et al. MDA7/IL-24 is a unique cytokine in the IL-10 family. Int Immunopharmacol 2004;4:649-67.
18. Jiang H, Su ZZ, Lin JJ, et al. The melanoma differentiation associated gene MDA7 suppresses cancer cell growth. Proc Natl Acad Sci USA 1996;93:9160-5.
19. Su ZZ, Madireddi MT, Lin JJ, et al. The cancer growth suppressor gene MDA7 selectively induces apoptosis in human breast cancer cells and inhibits tumor growth in nude mice. Proc Natl Acad Sci USA 1998;95:14400-5.
20. Ekmekcioglu S, Ellerhorst J, Mhashilkar A, et al. Down-regulation of melanoma differentiation associated gene (MDA7) expression in human melanomas. Int J Cancer 2001;94:54-9.
21. Sarkar D, Su ZZ, Lebedeva IV, et al. MDA7 (IL-24) mediates selective apoptosis in human melanoma cells by inducing the coordinated overexpression of the GADD family of genes by means of p38 MAPK. Proc Natl Acad Sci USA 2002;99:10054-9.
22. Mhashilkar AM, Schrock RD, Hindi M, et al. Melanoma differentiation associated gene-7 (MDA7): a novel anti-tumor gene for cancer gene therapy. Mol Med 2001;7:271-82.
23. Kawabe S, Nishikawa T, Munshi A, et al. Adenovirus mediated MDA7 gene expression radiosensitizes non-small lung cancer cells via p53-independent mechanisms. Mol Ther 2002;6:637-44.
24. Rampino N, Yamamoto H, Ionov Y, et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science (Wash DC) 1997;275:967-9.
25. Caudell EG, Mumm JB, Poindexter N, et al. The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24. J Immunol 2002;168:6041-6.
26. Neumann D, Lienenklaus S, Rosati O, Martin MU. IL-1beta-induced phosphorylation of PKB/Akt depends on the presence of IRAK-1. Eur J Immunol 2002;32:3689-98.
27. Bowie A, O'Neill LA. The interleukin-1 receptor/Toll-like receptor superfamily: signal generators for pro-inflammatory interleukins and microbial products. J Leukoc Biol 2000;67:508-14.
28. Rock FL, Hardiman G, Timans JC, Kastelein RA, Bazan JF. A family of human receptors structurally related to Drosophila Toll. Proc Natl Acad Sci USA 1998;95:588-93.
29. Janssens S, Beyaert R. Functional diversity and regulation of different interleukin-1 receptor-associated kinase (IRAK) family members. Mol Cell 2003;11:293-302.
30. Janssens S, Burns K, Tschopp J, Beyaert R. Regulation of interleukin-1- and lipopolysaccharide-induced NF-kappaB activation by alternative splicing of MyD88. Curr Biol 2002;12:467-71.
31. Jiang Z, Zamanian-Daryoush M, Nie H, et al. Poly(I-C)-induced Toll-like receptor 3 (TLR3)-mediated activation of NFkappa B and MAP kinase is through an interleukin-1 receptor-associated kinase (IRAK)-independent pathway employing the signaling components TLR3-TRAF6-TAK1-TAB2-PKR. J Biol Chem 2003;278:16713-19.
32. Nomura F, Kawai T, Nakanishi K, Akira S. NF-kappaB activation through IKK-i-dependent 1-TRAF/TANK phosphorylation. Genes Cells 2000;5:191-202.
33. Baltathakis I, Alcantara O, Boldt DH. Expression of different NF-kappaB pathway genes in dendritic cells (DCs) or macrophages assessed by gene expression profiling. J Cell Biochem 2001;83:281-90.
34. Wajant H, Henkler F, Scheurich P. The TNF-receptor-associated factor family: scaffold molecules for cytokine receptors, kinases and their regulators. Cell Signal 2001;13:389-400.
35. Acharya A, Singh SM. Effect of TNF-alpha on the induction of apoptosis in murine macrophages: role of interleukin-1 beta converting enzyme. Int J Immunopathol Pharmacol 2001;14:5-10.
36. Rossi D, Gaidano G. Messengers of cell death: apoptotic signaling in health and disease. Haematologica 2003;88:212-8.
37. You Z, Ouyang H, Lopatin D, Polver PJ, Wang CY. Nuclear factor-kappa B-inducible death effector domain-containing protein suppresses tumor necrosis factor-mediated apoptosis by inhibiting caspase-8 activity. J Biol Chem 2001;276:26398-404.
38. Kumar D, Whiteside TL, Kasid U. Identification of a novel tumor necrosis factor-alpha-inducible gene, SCCS2, containing the consensus sequence of a death effector domain of fas-associated death domain-like interleukin-1beta- converting enzyme-inhibitory protein. J Biol Chem 2000;275:2973-8.
39. Taniguchi T, Takaoka A. A weak signal for strong responses: interferon-alpha/beta revisited. Nat Rev Mol Cell Biol 2001;2:378-86.
40. Kim KB, Choi YH, Kim IK, et al. Potentiation of Fas- and TRAIL-mediated apoptosis by IFN-gamma in A549 lung epithelial cells: enhancement of caspase-8 expression through IFN-response element. Cytokine 2002;20:283-8.
41. Kumar A, Commane M, Flickinger TW, Horvath CM, Stark GR. Defective TNF-alpha-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases. Science (Wash DC) 1997;278:1630-2.
42. Sedger LM, Shows DM, Blanton RA, et al. IFN-gamma mediates a novel antiviral activity through dynamic modulation of TRAIL and TRAIL receptor expression. J Immunol 1999;163:920-6.
43. Park SY, Billiar TR, Seol DW. IFN-gamma inhibition of TRAIL-induced IAP-2 upregulation, a possible mechanism of IFN-gamma-enhanced TRAIL-induced apoptosis. Biochem Biophys Res Commun 2002;291:233-6.
44. Tomita Y, Bilim V, Hara N, Kasahara T, Takahashi K. Role of IRF-1 and caspase-7 in IFN-gamma enhancement of Fas-mediated apoptosis in ACHN renal cell carcinoma cells. Int J Cancer 2003;104:400-8.
45. Shigeno M, Nakao K, Ichikawa T, et al. Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation. Oncogene 2003;22:1653-62.
46. Kirchhoff S, Schaper F, Hauser H. Interferon regulatory factor 1 (IRF-1) mediates cell growth inhibition by transactivation of downstream target genes. Nucleic Acids Res 1993;21:2881-9.
47. Wessely R, Hengst L, Jaschke B, et al. A central role of interferon regulatory factor-1 for the limitation of neointimal hyperplasia. Hum Mol Genet 2003;12:177-87.
48. Yonemitsu Y, Kaneda Y, Tanaka S, et al. Transfer of wild-type p53 gene effectively inhibits vascular smooth muscle cell proliferation in vitro and in vivo. Circ Res 1998;82:147-56.
49. D'Cunha J, Knight E Jr, Haas AL, Truitt RL, Borden EC. Immunoregulatory properties of ISG15, an interferon-induced cytokine. Proc Natl Acad Sci USA 1996;93:211-5.
50. Fukuda A, Tokonabe S, Hamada M, et al. Alleviation of PC4- mediated transcriptional repression by the ERCC3 helicase activity of general transcription factor TFIIH. J Biol Chem 2003;278:14827-31.
51. Johnsen SA, Subramaniam M, Katagiri T, Janknecht R, Speisberg TC. Transcriptional regulation of Smad2 is required for enhancement of TGFbeta/Smad signaling by TGFbeta inducible early gene. J Cell Biochem 2002;87:233-41.
52. Goumans MJ, Mummery C. Functional analysis of the TGFbeta receptor/Smad pathway through gene ablation in mice. Int J Dev Biol 2000;44:253-65.
53. Miyazono K, Suzuki H, Imamura T. Regulation of TGF-beta signaling and its roles in progression of tumors. Cancer Sci 2003;94:230-4.
54. ten Dijke P, Miyazono K, Heldin CH. Signaling inputs converge on nuclear effectors in TGF-beta signaling. Trends Biochem Sci 2000;25:64-70.
55. Johnsen SA, Subramaniam M, Janknecht R, Speisberg TC. TGFbeta inducible early gene enhances TGFbeta/Smad-dependent transcriptional responses. Oncogene 2002;21:5783-90.
56. Bakin AV, Tomlinson AK, Bhowmick NA, Moses HL, Arteaga CL. Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. J Biol Chem 2000;275:36803-10.
57. Hocevar BA, Brown TL, Howe PH. TGF-beta induces fibronectin synthesis through a c-Jun N-terminal kinase-dependent, Smad4-independent pathway. EMBO J 1999;18:1345-56.
58. Imai K, Takeshita A, Hanazawa S. TGF-beta inhibits lipopolysaccharide- stimulated activity of c-Jun N-terminal kinase in mouse macrophages. FEBS Lett 1999;456:375-8.
59. Sano Y, Harada J, Tashiro S, et al. ATF-2 is a common nuclear target of Smad and TAK1 pathways in transforming growth factor-beta signaling. J Biol Chem 1999;274:8949-57.
60. Dennler S, Itoh S, Vivien D, et al. Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J 1998;17:3091-100.
61. Moustakas A, Kardassis D. Regulation of the human p21/WAF1/Cip1 promoter in hepatic cells by functional interactions between SpI and Smad family members. Proc Natl Acad Sci USA 1998;95:6733-8.
62. Verrecchia F, Tacheau C, Schorpp-Kistner M, Angel P, Mauviel A. Induction of the AP-1 members c-Jun and JunB by TGF-beta/Smad suppresses early Smad-driven gene activation. Oncogene 2001;20:2205-11.
63. Hall MC, Young DA, Waters JG, et al. The comparative role of activator protein 1 and Smad factors in the regulation of Timp-1 and MMP-1 gene expression by transforming growth factor-beta 1. J Biol Chem 2003;278:10304-13.
64. Frey RS, Mulder KM. Involvement of extracellular signal-regulated kinase 2 and stress-activated protein kinase/Jun N-terminal kinase activation by transforming growth factor beta in the negative growth control of breast cancer cells. Cancer Res 1997;57:628-33.
65. Hirao A, Kong YY, Matsuoka S, et al. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science (Wash DC) 2000;287:1824-7.
66. Mori T, Anazawa Y, Iiizumi M, et al. Identification of the interferon regulatory factor 5 gene (IRF-5) as a direct target for p53. Oncogene 2002;21:2914-18.